Isu Group is accelerating expansion into future businesses on the back of improved performance at key affiliates. Isu Group said on Aug. 24 it held a “2026 Integrated IR Day” on Aug. 18 to share affiliates’ first-half business results and mid- to long-term growth strategies.

Isu Chemical, Isu Petasys, Isu Speciality Chemical and Isu Abxis took part. They introduced first-half results and business updates and presented strategies including future growth businesses such as AI, batteries and bio.

Marking its 30th anniversary this year, Isu Group presented an integrated vision to expand new growth engines based on the competitiveness of its existing businesses. Isu Chemical is seeking new businesses on the back of a stable business foundation. Isu Petasys is positioning AI high-performance hardware as a growth pillar, Isu Speciality Chemical battery materials, and Isu Abxis bio and healthcare.

Isu Petasys posted its highest quarterly results on record, helped by expanding investment by big tech in AI data centers. Second-quarter consolidated revenue rose 57 percent from a year earlier to 379.9 billion won, and operating profit increased 83 percent to 77.1 billion won. The operating margin was 20.3 percent. A higher share of high-margin products such as AI accelerators and 800G-class switches drove results. The company forecast annual revenue-based production capacity would exceed 2 trillion won by 2028.

Isu Chemical posted record results, with first-half consolidated revenue of 1.38 trillion won and operating profit of 122 billion won. The company said it secured cost competitiveness by promoting vertical integration of normal paraffin and linear alkylbenzene. Isu Speciality Chemical posted second-quarter revenue of 108 billion won and operating profit of 7.7 billion won, and is preparing for normal operations in the second half after completing early construction of a commercialization facility for lithium sulfide, a key material for all-solid-state batteries. Isu Abxis is seeking to secure growth engines in bio and healthcare with an Opdivo biosimilar and an antibody new-drug pipeline.

An Isu Group official said, “Based on the competitiveness of each affiliate, we are expanding our business areas into AI, batteries and bio and building a new foundation for growth.” The official added, “On this basis, we are stepping up the group’s integrated growth strategy in earnest with the goal of achieving 6 trillion won in revenue and 600 billion won in operating profit in 2030.”